News | January 20, 2015

University of Tennessee Engineering Research Offers Hope for Heart Valve Patients

Teams working to create calcification-proof tissue-engineered heart valves

Tennessee, Knoxville, heart valve, tissue engineered, calcification proof

January 20, 2015 — There could soon be new hope for those facing one of humanity's biggest health issues, thanks to research from the University of Tennessee Knoxville College of Engineering. 

Cardiovascular diseases are the world's number one cause of death, with some estimates indicating that as many as one-third of the planet's deaths in a given year are attributable to some form of the disease. 

While heart valve disease is only one of many afflictions falling under that heading, its widespread impact — affecting up to 30 percent of the elderly population in developed countries alone — makes it a key component of the overall problem of heart-related ailments.

Zannatul Ferdous, an assistant professor in UT's Department of Mechanical, Aerospace, and Biomedical Engineering, leads a research team addressing the issue, thanks in part to a BRIGE — Broadening Participation Research Initiation Grants in Engineering — grant from the National Science Foundation.

"Currently, the treatment option for valve disease is mainly end-stage replacement or repair surgeries, and no early treatment or detection options exist," said Ferdous. "The goal of our lab is to understand these diseases and develop alternate treatment options such as functional tissue-engineered heart valves."

One of the main issues with heart valves that the group is focusing on is what is known as calcification, a process where calcium deposits build up on the valves, eventually restricting the flow of blood through the heart. 

By studying the root causes of calcification and constructing new heart valves through tissue engineering — using cells to construct organic human tissue — Ferdous and her group aim to eventually develop calcification-proof valves. 

“We are tackling calcification head-on, looking at risk factors from everything like age and gender to chemical factors and cell characteristics," said Ferdous. "At the same time, we are developing custom devices that will allow us to truly mimic all the forces at play in the heart.”

For more information: www.mabe.utk.edu

Related Content

Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Overlay Init